Condition: Myelodysplastic Syndrome · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Sponsor: Traws Pharma, Inc.
This study, is a Phase I/II clinical trial in three parts: Phase I Dose Escalation, Phase II, Part 1 RPTD Cohort, and Phase II, Part 2 Expansion. The first two parts have been completed. The Phase II, Part 2 Expansion will assess if treatment with rigosertib in combination with azacitidine, has measurable effects in patients with myelodysplastic syndrome (MDS). Safety of patients is an objective throughout all parts of the study.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| City of Hope | Duarte, California, United States | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage, California, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| Cancer Center of Kansas | Wichita, Kansas, United States | — |
| Saint Louis University | St Louis, Missouri, United States | — |
| Roswell Park Cancer Institute | Buffalo, New York, United States | — |
| Mount Sinai Medical Center | New York, New York, United States | — |
| White Plains Hospital Center for Cancer Care | White Plains, New York, United States | — |
| Carolina Blood and Cancer Care Associates | Rock Hill, South Carolina, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | — |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01926587